TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12523915

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (patients not using CPAP)
Number of subjects: 331
Study: 10849243

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zolpidem and Placebo
Number of subjects: 8
Study: 8538349

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 81
Study: 1651738

Group type: EXPERIMENTAL
Intervention: Low-dose ANP infusion (0.005 microgram/kg/min for 1 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose ANP infusion (0.05 microgram/kg/min for 1 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (baseline levels)
Number of subjects: 12
Study: 6341102

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg daily per os
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral disodium cromoglycate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10
Study: 31210177

Group type: EXPERIMENTAL
Intervention: Tavipec® (Spicae aetheroleum) 150 mg, 2 capsules thrice daily for 7 days
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 29694963

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study: 26758999

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during percutaneous coronary intervention (PCI)
Number of subjects: 7244

Group type: COMPARATOR
Intervention: PCI-only
Number of subjects: 7244

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI
Number of subjects: 7244
Study: 24483158

Group type: EXPERIMENTAL
Intervention: PDRN
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 23030673

Group type: EXPERIMENTAL
Intervention: Water ingestion (50 mL)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Water ingestion (500 mL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no water ingestion)
Number of subjects: 19
Study: 20306530

Group type: EXPERIMENTAL
Intervention: Compression bandaging for 24 hours
Number of subjects: 124

Group type: COMPARATOR
Intervention: Compression bandaging for 5 days
Number of subjects: 124
Study: 17147487

Group type: EXPERIMENTAL
Intervention: High levels of physical activity (PA)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Calcium intake (CI) in excess of 1039 mg/day
Number of subjects: 1008

Group type: COMPARATOR
Intervention: High levels of physical activity (PA) and low calcium intake (CI)
Number of subjects: 1008
Study: 16311449

Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intracranial blood volume (IBV) pulse waveforms
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 75
Study: 11927731

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine coadministered with Hib vaccines (groups 1-4)
Number of subjects: 5318

Group type: COMPARATOR
Intervention: Commercially available control vaccines (DTPa, Hib, and OPV) administered separately (group 5)
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine
Number of subjects: 5318

Group type: EXPERIMENTAL
Intervention: Hib N meningitidis outer-membrane complex protein conjugate vaccine
Number of subjects: 5318
Study: 10216145

Group type: EXPERIMENTAL
Intervention: Interferon therapy (9 million units three times a week for 38 +/- 8 weeks or 49 +/- 13 weeks)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Interferon therapy (44.8 +/- 27.4 weeks)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 157
Study: 8785887

Group type: EXPERIMENTAL
Intervention: Topical treatment with calcipotriene
Number of subjects: 0
Study: 2131925

Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg bd
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ranitidine 300mg bd
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg at bedtime (maintenance)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ranitidine 300mg at bedtime (maintenance)
Number of subjects: 75
Study: 92202

Group type: EXPERIMENTAL
Intervention: Direct argon laser photocoagulation to the fluorescein leaking site
Number of subjects: 2

Group type: COMPARATOR
Intervention: Indirect treatment away from the leak
Number of subjects: 2
Study: 31925579

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Number of subjects: 240

Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 240
Study: 31540168

Group type: EXPERIMENTAL
Intervention: Interdisciplinary weight loss and lifestyle intervention combined with usual care
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care (i.e., continuous positive airway pressure)
Number of subjects: 84
Study: 28731642

Group type: EXPERIMENTAL
Intervention: Highest quartile of diet quality (total food score > 36)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Lowest quartile of diet quality (total food score < 36)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Quartiles of diet quality
Number of subjects: 146
Study: 25346345

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Group (PRTG)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Psychoeducation Group (PEG)
Number of subjects: 53
Study: 24163593

Group type: EXPERIMENTAL
Intervention: Student peer assessment (SPA) training, practice with assessment rubrics, and application of anonymous SPA to assignments.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no SPA training).
Number of subjects: 71
Study: 21719638

Group type: EXPERIMENTAL
Intervention: COPCA
Number of subjects: 46

Group type: COMPARATOR
Intervention: TIP
Number of subjects: 46
Study: 20020572

Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Lasofoxifene
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 8556
Study: 16938689

Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 128
Study: 15231008

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (500 IU/day) and calcium (500 mg/day) during winter months (October-April)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No supplements (control group)
Number of subjects: 55
Study: 11420592

Group type: EXPERIMENTAL
Intervention: Suctioning techniques (including preoxygenation, hyperinflation, insufflation, hyperoxygenation, hyperventilation, saline instillation, adaptor use, medication use, open and closed systems, and various types of catheters)
Number of subjects: 0
Study: 9243440

Group type: EXPERIMENTAL
Intervention: Recorded delivery reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone reminders
Number of subjects: 0
Study: 8420303

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 2870956

Group type: EXPERIMENTAL
Intervention: Terbutaline 0.25 +/- 0.25 mg iv
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prenalterol 1 mg iv
Number of subjects: 9

Group type: COMPARATOR
Intervention: Metoprolol 15 mg iv (pretreatment)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Propranolol 10 mg iv (pretreatment)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Metoprolol infusion
Number of subjects: 9
Study: 30074128

Group type: EXPERIMENTAL
Intervention: Prasugrel 3.75 mg/day
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg/day
Number of subjects: 129

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 129
Study: 26922192

Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Telehealth Parent-Mediated Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-Directed Telehealth Parent-Mediated Intervention
Number of subjects: 0
Study: 24808022

Group type: EXPERIMENTAL
Intervention: PDE5 inhibition with tadalafil or sildenafil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corticosteroids alone or in combination with cardioprotective medication
Number of subjects: 20
Study: 22825506

Group type: EXPERIMENTAL
Intervention: DC/CIK immunobiological cancer therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no DC/CIK treatment)
Number of subjects: 60
Study: 20520285

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study: 18179734

Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 65

Group type: COMPARATOR
Intervention: sodium picosulphate + magnesium citrate
Number of subjects: 65
Study: 16160068

Group type: COMPARATOR
Intervention: Standard initiation dose of 5 mg warfarin/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Model-based dosing using rapid CYP2C9 genotyping
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Model-based dosing
Number of subjects: 43
Study: 12694895

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11057425

Group type: EXPERIMENTAL
Intervention: 17beta‐oestradiol plus cyclic norethisterone acetate (NETA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9049193

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg daily administered orally (group 1)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Norfloxacin only during hospitalization (group 2)
Number of subjects: 109
Study: 8055501

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional brush
Number of subjects: 60
Study: 3098141

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (SCG) administered for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Matching placebo administered for 8 weeks
Number of subjects: 31
Study: 31570825

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study: 29678563

Group type: EXPERIMENTAL
Intervention: FIT Teens (integrated Cognitive-Behavioral Therapy and specialized neuromuscular exercise training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 40
Study: 26896828

Group type: EXPERIMENTAL
Intervention: BIIB023 (3 or 20 mg kg(‐1) administered by intravenous infusion on Day 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BIIB023
Number of subjects: 0
Study: 24833648

Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction
Number of subjects: 216
Study: 23601577

Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel 4 to 8 hours before PCI (n=122)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo (n=120)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 600-mg loading dose of clopidogrel
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 20808814

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BCG naïve (Group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BCG vaccination at 4(1/2) months of age (Group 2 after vaccination)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TST responders
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TST induration
Number of subjects: 100
Study: 18845807

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 1007
Study: 17018460

Group type: EXPERIMENTAL
Intervention: Clinician prompting group (single‐page prompt including the child's symptoms and guideline recommendations given to the clinician at the time of the visit)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Clinician prompting group
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard-care group (no prompt given)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 226
Study: 14616928

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: naratriptan 2.5 mg
Number of subjects: 548

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study: 10910788

Group type: EXPERIMENTAL
Intervention: Higher level of initial exposure and postearthquake support (Village 1)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Lower level of initial exposure and less postearthquake support (Village 2)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Both villages assessed for PTSD using DSM-IV and DSM-III-R criteria
Number of subjects: 338
Study: 8607474

Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement with 100 gm of force
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (premolar not treated)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Headgear/biteplate and bionator groups
Number of subjects: 33
Study: 29302704

Group type: EXPERIMENTAL
Intervention: SEQ-IMRT
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 209
Study: 27607864

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms orally)
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 1721
Study: 26633750

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Novel ankle self-stretching using a strap (SSS)
Number of subjects: 32
Study: 22941872

Group type: COMPARATOR
Intervention: Single hemodialysis session
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Chronic vitamin E supplementation (800 IU/day)
Number of subjects: 19
Study: 20393270

Group type: EXPERIMENTAL
Intervention: Painful stimulation of the symptomatic hand in CRPS patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Painful stimulation of both hands in CRPS patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Painful stimulation in healthy controls
Number of subjects: 10
Study: 18612575

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nondirective reflective listening
Number of subjects: 122

Group type: COMPARATOR
Intervention: No further counseling
Number of subjects: 122
Study: 16040403

Group type: EXPERIMENTAL
Intervention: Citric acid alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malic acid alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined exposure of fruit acids (citric or malic) with 0.5% sodium lauryl sulphate (SLS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) with water
Number of subjects: 0
Study: 11833825

Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine (groups AI, AII, AIII)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intramuscular virosomal subunit vaccine (group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both vaccine formulations
Number of subjects: 88
Study: 10073636

Group type: EXPERIMENTAL
Intervention: Omafilcon A lenses (Proclear)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control lenses (subjects' own daily wear soft lenses)
Number of subjects: 76
Study: 7710021

Group type: EXPERIMENTAL
Intervention: Pre-operative measurement using paracetamol absorption technique
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Post-operative measurement using paracetamol absorption technique
Number of subjects: 14
Study: 1975334

Group type: EXPERIMENTAL
Intervention: 0.5 mg cromakalim
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.25 mg cromakalim
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7270569

Group type: EXPERIMENTAL
Intervention: Ampicillin (AMP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefamandole (CEF)
Number of subjects: 30
Study: 31760314

Group type: EXPERIMENTAL
Intervention: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with gemcitabine or mFOLFOX6
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (gemcitabine or mFOLFOX6 alone)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy
Number of subjects: 141
Study: 30993900

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite Clinical Trials Version (IWQOL-Lite-CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight and body mass index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite-CT
Number of subjects: 0
Study: 28720242

Group type: EXPERIMENTAL
Intervention: Family social support intervention including a family caregiver
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group without family caregiver support
Number of subjects: 164
Study: 25784662

Group type: EXPERIMENTAL
Intervention: GLICEMIA program (12-month prevention program with three individual counseling appointments and five educational group sessions)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Control group (only information about health obtained in three assessments)
Number of subjects: 1092
Study: 23660742

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the right inferior frontal gyrus (rIFG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TMS (control condition)
Number of subjects: 0
Study: 21477929

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 19716144

Group type: EXPERIMENTAL
Intervention: Omegaven (4-hour lipid infusion contributing 0.04 g/kg of marine n-3 FA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intralipid (4-hour lipid infusion)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omegaven
Number of subjects: 11
Study: 17978709

Group type: EXPERIMENTAL
Intervention: Continuation of antiplatelet therapy during surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Discontinuation of antiplatelet therapy and substitution with flurbiprofen or isocoagulant fractionated heparin or calcium heparin
Number of subjects: 60
Study: 14731178

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with resorbable membranes and a bone substitute
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with non-resorbable membranes with or without a bone substitute
Number of subjects: 30
Study: 11726435

Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 20
Study: 9205764

Group type: EXPERIMENTAL
Intervention: ebrotidine 400 mg
Number of subjects: 478

Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: ebrotidine 400 mg (smokers)
Number of subjects: 478

Group type: COMPARATOR
Intervention: ranitidine 300 mg (smokers)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: ebrotidine (non-smokers)
Number of subjects: 478

Group type: COMPARATOR
Intervention: ranitidine (non-smokers)
Number of subjects: 478
Study: 8485019

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BRL 46470A (0.1 microgram, 0.01 mg, 1 mg or 50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2889678

Group type: EXPERIMENTAL
Intervention: Procaterol 20 mcg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol 400 mcg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Procaterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 12
Study: 29684515

Group type: EXPERIMENTAL
Intervention: Full Power-Assisted (FPA) technique
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional Freehand (FH) technique
Number of subjects: 105
Study: 28796874

Group type: EXPERIMENTAL
Intervention: Hard first (N = 8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Easy first (N = 10)
Number of subjects: 18
Study: 26200404

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Periarticular infiltration analgesia (PIA)
Number of subjects: 60
Study: 23010452

Group type: EXPERIMENTAL
Intervention: 2.5g/day n-3 PUFAs
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 1.25g/day n-3 PUFAs
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 106
Study: 21957874

Group type: EXPERIMENTAL
Intervention: Chickpea
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lentil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yellow Split Pea
Number of subjects: 25

Group type: COMPARATOR
Intervention: Macaroni and Cheese (Control)
Number of subjects: 25
Study: 18283572

Group type: EXPERIMENTAL
Intervention: XCaliber pins (Orthofix)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard pins (Orthofix)
Number of subjects: 50
Study: 17064611

Group type: EXPERIMENTAL
Intervention: High intensity physical activity
Number of subjects: 50494

Group type: COMPARATOR
Intervention: Moderate intensity physical activity of 151 - 300 minutes/week
Number of subjects: 50494

Group type: COMPARATOR
Intervention: Moderate intensity physical activity over 300 minutes/week
Number of subjects: 50494

Group type: COMPARATOR
Intervention: Low-level physical activity of 301 - 420 minutes/week
Number of subjects: 50494

Group type: COMPARATOR
Intervention: Low-level physical activity over 420 minutes/week
Number of subjects: 50494

Group type: COMPARATOR
Intervention: Vigorous physical activity over 150 minutes/week
Number of subjects: 50494
Study: 12025709

Group type: EXPERIMENTAL
Intervention: Supplementary written drug information
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no supplementary written drug information)
Number of subjects: 78
Study: 10855346

Group type: EXPERIMENTAL
Intervention: 16-week multidrug regimen
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard CAF regimen
Number of subjects: 163
Study: 7677827

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.25 micrograms (titrated according to serum calcium concentration)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 176